Related references
Note: Only part of the references are listed.From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease
R. Rene et al.
NEUROLOGIA (2014)
Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease
George Grossberg et al.
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS (2013)
Diagnosis and Management of the Patient with Suspected Dementia in Primary Care
Stefan Holzer et al.
DRUGS & AGING (2013)
Predictors of response to the 13.3 and 9.5mg/24h rivastigmine patch: The optimizing /INS;transdermal exelon in mild-to-moderate Alzheimer's disease (optima) study
J.L. Molinuevo et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
High-dose 13.3mg/24h rivastigmine patch efficacy and safety in mild-to-moderate Alzheimer's disease with and without concomitant memantine use
J.L. Molinuevo et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time-to-meet decline
Sandra Black et al.
Alzheimers & Dementia (2012)
Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimer's Disease
Jeffrey Cummings et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2012)
Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time
O. Riedel et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA (2012)
Effects of Body Weight on Tolerability of Rivastigmine Transdermal Patch A Post-hoc Analysis of a Double-blind Trial in Patients With Alzheimer Disease
Jae-Hong Lee et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2011)
Transdermal Rivastigmine Management of Cutaneous Adverse Events and Review of the Literature
Jill Greenspoon et al.
CNS DRUGS (2011)
Rivastigmine Transdermal Patch A Review of its Use in the Management of Dementia of the Alzheimer's Type
Sohita Dhillon
DRUGS (2011)
The Inhibitory Effect of Rivastigmine and Galantamine on Choline Transport in Brain Capillary Endothelial Cells
Na-Young Lee et al.
BIOMOLECULES & THERAPEUTICS (2010)
EFNS guidelines for the diagnosis and management of Alzheimer's disease
J. Hort et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
G. T. Grossberg et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch
Gilbert Lefevre et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Current Pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2008)
Dementia of the Alzheimer Type
Jessica J. Jalbert et al.
EPIDEMIOLOGIC REVIEWS (2008)
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients
G. Lefevre et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease
Rafael Blesa et al.
NEUROLOGY (2007)
Rationale for transdermal drug administration in Alzheimer disease
Wolfgang Oertel et al.
NEUROLOGY (2007)
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease
Bengt Winblad et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers:: Relative effects of body site application
Gilbert Lefevre et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Rivastigmine transidermal patch: In the treatment of dementia of the Alzheimer's type
Lily P. H. Yang et al.
CNS DRUGS (2007)
Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease
S Muhlack et al.
PHARMACOPSYCHIATRY (2006)
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles
MF Eskander et al.
BRAIN RESEARCH (2005)
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
R Bullock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development
AV Terry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Inhibition of human cholinesterases by drugs used to treat Alzheimer disease
S Darvesh et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2003)
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain
Z Rakonczay
ACTA BIOLOGICA HUNGARICA (2003)
Cost of dementia: impact of disease progression estimated in longitudinal data
CK Andersen et al.
SCANDINAVIAN JOURNAL OF PUBLIC HEALTH (2003)
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
MW Jann
PHARMACOTHERAPY (2000)
Share Paper
